Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Regeneron Profit Drops on Higher Research, Development Spending

AI-generated analysis

πŸ“‰ Regeneron Pharmaceuticals' first-quarter net income declined to $727.2 million, representing a drop of $81.5 million compared to the same quarter last year.

πŸ’° The quarterly earnings per share fell to $6.75 from $7.27 a year ago due to increased spending on research and development.

πŸ“Š Adjusted earnings stood at $9.47 per share, which exceeded the average Wall Street analyst target of $8.89 per share.

πŸš€ Total revenue increased by 19% year-over-year to reach $3.61 billion, surpassing analyst expectations of $3.48 billion.

πŸ’Š Sales of Dupixent, used for eczema and asthma, grew significantly by 33% to total $4.9 billion in the quarter.

🀝 Regeneron's collaboration revenue from its partnership with Sanofi on Dupixent amounted to $1.61 billion.

πŸ“‰ Revenue from the standard formulation of the Eylea eye drug decreased by 10% to $941 million this quarter.

πŸ”¬ However, sales of the high-dose (Eylea HD) formulation of the same drug surged by 52% to reach $468 million.

πŸ§ͺ Research and development expenses rose sharply to $1.54 billion for the quarter from $1.33 billion in the prior year.

πŸ’Έ The company increased R&D spending primarily to offset the decline in standard Eylea sales with growth in Dupixent.

πŸ“… For the full year 2026, Regeneron reiterated its target range for total research-and-development expenses of $6.45 billion to $6.68 billion.

πŸ“Š After adjusting for stock-based compensation, management expects adjusted R&D expenses to fall between $5.9 billion and $6.1 billion in 2026.

Bullish Signals
  • Regeneron's revenue grew 19% year-over-year to $3.61 billion, surpassing the average analyst target of $3.48 billion.
  • Adjusted earnings reached $9.47 per share, exceeding Wall Street estimates of $8.89 per share and signaling strong operational performance despite one-off items.
  • Dupixent sales rose 33% to $4.9 billion, demonstrating sustained demand for the blockbuster drug in its partnership with Sanofi.
  • The Eylea HD formulation saw a significant 52% increase in sales, reaching $468 million, which helps offset declines in the standard formulation.
  • Management reiterated high R&D spending targets of $6.45 billion to $6.68 billion for 2026, indicating confidence in the long-term pipeline and growth opportunities.
Risk Factors
  • Regeneron's first-quarter net income fell by 8% to $727.2 million, dropping from $808.7 million a year earlier.
  • Increased research-and-development spending of $1.54 billion for the quarter directly offset growing sales of its key eye and eczema drugs.
  • Sales of the standard formulation of its Eylea ophthalmological drug fell 10% to $941 million, raising concerns about demand erosion in a core segment.
  • The company reiterated its target for research-and-development expenses between $6.45 billion and $6.68 billion for 2026, indicating sustained heavy investment pressure on profitability.
Full Analysis
Regeneron Pharmaceuticals reported a decline in first-quarter net income to $727.2 million, or $6.75 per share, from $808.7 million, or $7.27 per share, in the previous year's period. This decrease was primarily attributed to increased research and development spending of $1.54 billion for the quarter, compared to $1.33 billion a year earlier. Despite the drop in GAAP earnings, the company beat Wall Street expectations on an adjusted basis, reporting adjusted earnings of $9.47 per share against a consensus target of $8.89 per share. Revenue growth helped offset higher spending, with total revenue increasing by 19% to $3.61 billion, surpassing the average analyst target of $3.48 billion. The company's key asset, Dupixent for eczema and asthma, saw sales rise significantly by 33% to $4.9 billion, contributing $1.61 billion in collaboration revenue with partner Sanofi. Conversely, sales of the standard Eylea formulation decreased by 10% to $941 million, though this was partially offset by a 52% surge in sales of the Eylea HD formulation to $468 million. Looking ahead, Regeneron maintained its guidance for annual research and development expenses between $6.45 billion and $6.68 billion for the year 2026. When adjusted for stock-based compensation, the company expects R&D spending to fall within a range of $5.9 billion to $6.1 billion for the full year. This indicates that while the company is investing heavily in its pipeline, core revenue generation remains strong enough to support growth even as one-time earnings are impacted by these expenditures.